Reata’s Rare Genetic Disorder Drug gets US FDA Approval


Reata Pharmaceuticals Inc.’s drug for the treatment of a rare genetic disorder that causes progressive damage to the nervous system was approved by the U.S. Food and Drug Administration (FDA), prompting its shares to rise nearly 160% after the opening bell.

Skyclarys, Reata’s first approved product, is expected to sell for $400 million in the United States by 2030, according to Maury Raycroft, a Jefferies analyst.

According to Reata’s estimation, around 5,000 people in the United States suffer from the condition known as Friedreich’s ataxia.

A neuromuscular disorder known as Friedreich’s ataxia can result in muscle weakness, loss of coordination, and a wheelchair-bound patient in their mid-20s or even a premature death.

Prior to the FDA’s decision, Raycroft estimated that the drug could cost $425,000 per patient annually.

The FDA requested additional data, and a mid-stage study showed that patients who took Reata had better neurological functions like speaking, swallowing, and standing than those who took a placebo, according to the company’s case for approval.

READ  UK Records First Omicron Variant Death as its Spreads Rapidly Across the Country

In 2020, the FDA stated that there was insufficient evidence to warrant approval based on the single study; however, Reata has since submitted additional analyses without initiating a second clinical trial.

Aduhelm, a drug developed by Biogen Inc. for the treatment of Alzheimer’s disease, and Amylyx’s ALS, a drug developed by Amylyx, have both received prior FDA approval on the basis of sufficient data.